Navigation Links
SignalRX Pharmaceuticals Issued U.S. Patent Covering Novel Kinase Inhibitors For Treating Cancer and Other Diseases

SAN DIEGO, Nov. 12, 2013 /PRNewswire-iReach/ -- SignalRX Pharmaceuticals Inc., focused on developing more effective oncology drugs through molecular design imparting multiple target inhibition, today announced the issuance of U.S. Patent No. 8,557,807 entitled "Thienopyranones as kinase inhibitors" by the U.S. Patent and Trademark Office claiming composition of matter for a broad generic molecular scaffold (TP) of compounds that possess novel kinase inhibition profiles aimed at imparting maximum anticancer efficacy.  This U.S. patent grants coverage of the TP scaffold compounds into the year 2029 and is complemented by additional U.S. applications as well as by corresponding patent applications pending in other major markets throughout the world. 

The compounds covered in the patent inhibit PI3 kinase and several other key cancer target kinases such as mTORC1, mTORC2, DNA-PK, PLK1 and PIM1.  Further mechanisms of action include induction of oxidative stress and demonstrated anti-cancer stem cell activity.   Furthermore, certain of these compounds can be molecularly manipulated to maintain their PI3 kinase inhibitory activity while simultaneously also inhibiting certain other key cancer targets providing dual inhibition from a single molecule, in line with the CRIMP (Control Resulting from Inhibition of Multiple Pathways) platform which is focused on the development of more effective cancer treatments.  Additionally, other diseases besides cancer such as, age-related macular degeneration and autoimmune diseases along with various inflammatory diseases all potentially can be treated by the kinase inhibition properties of these compounds.

"This patent is a key member of our growing intellectual property portfolio as it provides protection for the cutting edge efforts to deliberately design molecules having multiple mechanisms of action to overcome the devastating ability of cancer cells to shrug off treatments or to develop resistance or re-establish itself via cancer stem cells," said Donald L. Durden, MD, PhD, SignalRx President and Chief Executive Officer.  "We are among a select group of cancer researchers who are actively developing anticancer drugs with dual inhibitory properties including PI3K/MEK, PI3K/BRAF, PI3K/HDAC, PI3K/PARP, and PI3K/BET bromodomain setting the stage for the most efficacious smart combination anticancer treatments based on evolving cancer biology and personalized oncology paradigms.  In addition, these dual inhibitory drugs solve the problem of early stage clinical trial evaluation of multiple combinations by consolidating at least two of the combination partners into one drug.  Moreover, one molecule hitting two targets in the same cell is the only way to ensure that desired simultaneous blockage of both signaling pathways is achieved in vivo because two separate drugs will always suffer from differing cell penetration, metabolism, pharmacokinetics, etc., which promotes  tumor cell resistance  by diminishing the time and likelihood that useful dual blockage is achieved."

Additional information about these compounds was recently published in the Journal of Medicinal Chemistry (February 14th 2013 issue, volume 56, pages 1922-1939).

About SignalRx Pharmaceuticals  Inc.

SignalRx is a privately held corporation developing small molecule inhibitors of key signaling pathways used by cancer and cancer stem cells to evade treatments.  Such key signaling pathways  include major cell survival mechanisms, epigenetic regulation processes, and  DNA repair actions  encompassing critical targets such as PI3K, MEK, BRAF, Wnt, HDAC,  DNMT, BET bromodomains, and PARP.  SignalRx is leveraging its expertise in PI3K pathway inhibition to be the leader in developing single molecule therapeutics that selectively  inhibit synergistic critical cancer pathways.  These designed multi-action therapeutics are expected to exhibit enhanced anticancer effects and are the result of an effort to be both efficacious and cost effective in an evolving price sensitive oncology environment relying increasingly on prohibitively expensive combination treatments. 

For additional information please visit our website ( or email us at

Media Contact: Joseph Garlich, SignalRx Pharmaceuticals Inc., 317-418-8246,

News distributed by PR Newswire iReach:

SOURCE SignalRx Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
Breaking Biology Technology:
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):